|
Trial #
|
Trial Sub- type
|
Title
|
|
NSABP-B-49
NCI
|
Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
|
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
|
|
CALGB-70305
NCI
|
Women with stage I-III breast cancer who are undergoing axillary lymph node dissection
|
A Randomized Study to Prevent Lymphedema in Women Treated for Breast Cancer
|
|
GSK
LPT112515
|
Metastatic
HER2-positive
|
A Randomized, Phase III, Open-label, Study of Lapatinib plus Trastuzumab versus Trastuzumab as Continued HER2 Suppression Therapy after Completion of First- or Second-line Trastuzumab plus Chemotherapy in Subjects with HER2-positive Metastatic Breast Cancer
|
|
NSABP-B-43
NCI
|
DCIS
HER2 -positive
|
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy
|
|
NSABP –B –47
NCI
|
HER2-Low ( 2+)
|
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
|
|
ML28257
Sponsor
Genentech
|
Metastatic
HER2-positive
|
An Observational Cohort Study Of Treatment Patterns And Outcomes In Patients With HER2 Positive (HER2+) Metastatic Breast Cancer
|
|
CBKM120F2303
Sponsor
Novartis Pharmaceuticals
|
Metastatic
HER2-negative
HR - positive
|
A phase III randomized, double blind, placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative AI treated, locally advanced or metastatic breast cancer who progressed on or after mTOR inhibitor based treatment
|
|
CRAD001Y2413
Sponsor
Novartis Pharmaceuticals Corp.
|
Metastatic
HER2- negative
HR – positive
Front - line
|
An open-label, phase II, single-arm study of everolimus in combination with letrozole in the treatment of postmenopausal women with estrogen receptor positive metastatic breast cancer
|
|
S1207
Lead Group:
SWOG
|
Metastatic
HER2- negative
ER or PR– positive
Adjuvant Therapy
|
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
***PRE-ACTIVATION: This Trial is Not Yet Open to Patient Enrollment by Novartis ***
|
